LSO Breakfast Series

Advances In Medical Technology

Guest Speakers:

• David Stuart: Director, Management Consulting and Life Sciences Senior Analyst, RSM
• Ken Hughes: Chief Operating Officer, Microbix
• Zayna Khayat: VP, Client Success & Growth, Teladoc Health Canada, Inc.

David Stuart,  Director, Management Consulting and Life Sciences Senior Analyst, RSM

About 

David Stuart is a director with RSM US LLP’s management consulting team responsible for supporting local and cross-border transactions, managing and leading mergers and acquisitions, and supporting strategy advisory services in the private and public company sectors.

In May 2020, David was selected as a senior analyst in RSM’s cutting-edge Industry Eminence Program, which positions its senior analysts to understand, forecast, and communicate economic, business, and technology trends shaping the industries RSM serves. In his senior analyst role, David’s focus is on the life sciences industry. He is based in the firm’s San Francisco office.

Experience 

David has more than ten years of capital markets and corporate finance experience focused on M&A, financial advisory, and helping clients assess and solve complex strategic issues. He directly manages a pool of experienced managers and analysts and leverages RSM’s full financial services offerings when required.

As a member of the Industry Eminence Program, David collaborates across all lines of business to grow the life sciences industry practice. He is focused on supporting RSM’s medical technology subsector within life sciences. He provides clients with thoughtful insights supported by industry data to help determine and analyze emerging sector trends and issues. Beyond life sciences, David also has deep experience in the technology, telecommunications, alternative energy, and consumer products sectors.

Prior to joining RSM, David worked at a large financial institution focused on transactions across the capital structure. He started his career at GE Capital serving the middle market. Born and raised in Canada, David recently transferred to RSM’s San Francisco office.

Professional Affiliations & Education

• Association for Corporate Growth, the board member
• Passed CFA Exam Level II (June 2019)
• Bachelor of Commerce, finance, University of Calgary

Ken Hughes,  Chief Operating Officer, Microbix

About Microbix Biosystems

Microbix develops proprietary biological technology solutions for human health and well-being, with over 100 skilled employees and sales nearing C$ 2.0 million per month. It makes a wide range of critical biological materials for the global diagnostics industry as it pertains to human infectious diseases, notable antigens for immunoassays, and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation and help ensure the quality of clinical diagnostic workflows. Microbix antigens enable the antibody tests of over 100 international diagnostics companies, while its QAPs are sold to clinical laboratory accreditation organizations, diagnostics companies, and clinical laboratories. Microbix QAPs are now available in over 30 countries. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed and provides CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport medium (DxTM™) to stabilize patient samples for lab-based molecular diagnostic testing and Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots. The company had been very active in Ontario’s COVID-19 pandemic response. Microbix is traded on the TSX and OTCQX, and is headquartered in Mississauga, Ontario.

Zayna Khayat

Zayna is VP of Growth & Client Success at Teladoc Health in Canada.  Zayna previously led the Futures team with national home healthcare and aging non-proift, SE Health, as their Future Strategist. Zayna is Faculty of Singularity University’ Exponential Medicine stream, and is adjunct faculty in the Health Sector Strategy stream at the Rotman School of Management at the University of Toronto. Dr. Khayat was previously the lead of health system innovation at MaRS Discovery District, a health innovation hub in Toronto, Canada. In 2017 she was seconded to the REshape Innovation Centre at Radboud university medical centre in the Netherlands. Zayna completed her Ph.D. in diabetes research from the University of Toronto (2001), followed by a career in strategy consulting, including as a Principal in the healthcare practice of The Boston Consulting Group (BCG). She currently resides in Toronto with her husband and three children and is proficient in French and Arabic languages.